The Chinese government has kickstarted a new round of a national drug hunting campaign involving the industry and academia, with the first two programs in lung and breast cancer launched this month.
Key Takeaways
- A new China government R&D support program will focus on four major chronic disease areas with high prevalence in China – cardiovascular, respiratory and metabolic diseases and malignant tumors.
- In 2023 and 2024, a total of CNY3.3bn ($449m) in central government funding have been earmarked for spending on two batches of drug development programs
Th fresh state-supported effort will be focused primarily on four major chronic conditions with a high prevalence in China – cardiovascular, respiratory and metabolic disorders, as well as malignant tumors, officials with China’s National Health Commission (NHC) said during the International